Login to Your Account



Esperion Makes Up Ground On Positive Phase II Results

By Randall Osborne


Thursday, November 6, 2003
After losing 26 percent of its stock value on rumors that upcoming news regarding its cardiovascular drug would be negative, Esperion Therapeutics Inc. recovered when positive data were published. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription